151 related articles for article (PubMed ID: 24476445)
1. Saxagliptin, alogliptin, and cardiovascular outcomes.
Standl E
N Engl J Med; 2014 Jan; 370(5):483. PubMed ID: 24476445
[No Abstract] [Full Text] [Related]
2. [New antihyperglycemic drugs. Examination of cardiovascular outcomes with alogliptin versus standard of care (EXAMINE) and saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI 53)].
Gallwitz B; Nitschmann S
Internist (Berl); 2014 Jul; 55(7):859-62. PubMed ID: 24969610
[No Abstract] [Full Text] [Related]
3. Diabetes: Cardiovascular safety of 'gliptin' therapy.
Lim GB
Nat Rev Cardiol; 2013 Nov; 10(11):616. PubMed ID: 24042219
[No Abstract] [Full Text] [Related]
4. Pharmacotherapy: Cardiovascular safety of antihyperglycaemic drugs in patients with type 2 diabetes mellitus.
Greenhill C
Nat Rev Endocrinol; 2013 Nov; 9(11):625. PubMed ID: 24061081
[No Abstract] [Full Text] [Related]
5. Gliptins - do they increase cardiovascular risk or benefit?
Doggrell SA; Dimmitt SB
Expert Opin Drug Saf; 2014 May; 13(5):675-80. PubMed ID: 24684173
[TBL] [Abstract][Full Text] [Related]
6. Saxagliptin, alogliptin, and cardiovascular outcomes.
White WB; Zannad F
N Engl J Med; 2014 Jan; 370(5):484. PubMed ID: 24482824
[No Abstract] [Full Text] [Related]
7. Saxagliptin, alogliptin, and cardiovascular outcomes.
Scirica BM; Braunwald E; Bhatt DL
N Engl J Med; 2014 Jan; 370(5):483-4. PubMed ID: 24476444
[No Abstract] [Full Text] [Related]
8. Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
Derosa G; Maffioli P
N Engl J Med; 2016 Mar; 374(11):1095. PubMed ID: 26981947
[No Abstract] [Full Text] [Related]
9. Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.
Schernthaner G; Cahn A; Raz I
Diabetes Care; 2016 Aug; 39 Suppl 2():S210-8. PubMed ID: 27440835
[No Abstract] [Full Text] [Related]
10. New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
Simó R; Hernández C
Rev Esp Cardiol (Engl Ed); 2016 Nov; 69(11):1005-1007. PubMed ID: 27659856
[No Abstract] [Full Text] [Related]
11. New oral hypoglycaemics fail to show cardiovascular benefits.
Cohen D
BMJ; 2013 Sep; 347():f5458. PubMed ID: 24014343
[No Abstract] [Full Text] [Related]
12. ACP Journal Club. In at-risk patients with type 2 diabetes, saxagliptin and placebo did not differ for CV events.
Morey-Vargas OL; Montori VM
Ann Intern Med; 2014 Jan; 160(2):JC8-9. PubMed ID: 24445719
[No Abstract] [Full Text] [Related]
13. Dipeptidyl peptidase-4 inhibitors and cardiovascular safety.
Davis TM
Med J Aust; 2014 May; 200(8):450-1. PubMed ID: 24794596
[No Abstract] [Full Text] [Related]
14. Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
White WB; Cannon CP; Heller SR; Nissen SE; Bergenstal RM; Bakris GL; Perez AT; Fleck PR; Mehta CR; Kupfer S; Wilson C; Cushman WC; Zannad F;
N Engl J Med; 2013 Oct; 369(14):1327-35. PubMed ID: 23992602
[TBL] [Abstract][Full Text] [Related]
15. [The TECOS, EXAMINE and SAVOR studies--how do they differ and what are their outcomes?].
Špinar J; Špinarová L; Vítovec J
Vnitr Lek; 2015 Nov; 61(11):976-83. PubMed ID: 26652787
[TBL] [Abstract][Full Text] [Related]
16. An update on the 'gliptins'.
Drug Ther Bull; 2016 Dec; 54(12):138-141. PubMed ID: 27979881
[TBL] [Abstract][Full Text] [Related]
17. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
Clifton P
Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
[TBL] [Abstract][Full Text] [Related]
18. In AF or VTE, warfarin dosing by genotype improved time in therapeutic range but not clinical outcomes.
Dunn A
Ann Intern Med; 2014 Mar; 160(6):JC9. PubMed ID: 24638187
[No Abstract] [Full Text] [Related]
19. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Frederich R; Wiviott SD; Hoffman EB; Cavender MA; Udell JA; Desai NR; Mosenzon O; McGuire DK; Ray KK; Leiter LA; Raz I;
N Engl J Med; 2013 Oct; 369(14):1317-26. PubMed ID: 23992601
[TBL] [Abstract][Full Text] [Related]
20. No benefit of saxagliptin on cardiovascular outcomes in type 2 diabetes mellitus: potential explanations.
Jialal I; Dhindsa S
Metab Syndr Relat Disord; 2014 Apr; 12(3):157-8. PubMed ID: 24520851
[No Abstract] [Full Text] [Related]
[Next] [New Search]
